<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193398</url>
  </required_header>
  <id_info>
    <org_study_id>NEP-MDD-201</org_study_id>
    <nct_id>NCT03193398</nct_id>
  </id_info>
  <brief_title>BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Study Of BTRX-246040 Administered Once Daily In Patients With Major Depressive Disorder With Or Without Anhedonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BlackThorn Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BlackThorn Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of
      up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-administered Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The change in MADRS total score between BTRX-246040 and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-administered Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>The change from baseline to Week 8</time_frame>
    <description>The change in MADRS-6 subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-administered Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>The change from baseline to Week 8</time_frame>
    <description>The change in MADRS individual items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS subscales, the anxiety subscale (HADS-A) and the depression subscale (HADS-D)</measure>
    <time_frame>The change from baseline to Week 8</time_frame>
    <description>The change in total scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dimensional Anhedonia Rating Scale (DARS)</measure>
    <time_frame>The change from baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Snaith-Hamilton Pleasure Scale (SHAPS)</measure>
    <time_frame>The change from baseline to Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>BTRX-246040</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administered orally as 1 capsule QD for 1 week, followed by 2 capsules QD for 7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTRX-246040 oral capsule(s)</intervention_name>
    <description>BTRX-246040 administered once daily to patients with MDD for 8 weeks</description>
    <arm_group_label>BTRX-246040</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule(s)</intervention_name>
    <description>administered once daily to patients with MDD for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of MDD as defined by DSM-5 criteria and have had at least 1
             prior major depressive episode in the past 10 years

          -  Patients must present with a new current episode of MDD and the duration of the
             current episode must be at least 4 weeks but not longer than 18 months.

          -  At Visit 1 (screening) and Visit 2 (baseline), patients must have clinically
             significant depressive symptoms defined by tandem (investigator- and
             computer-administered) Montgomery-Asberg Depression Rating Scale (MADRS) total scores
             ≥ 26 with a difference of ≤ 7 points between the Investigator- and
             computer-administered MADRS total scores

          -  Patients must have a CGI-S score ≥ 4 at Visit 2 (baseline).

        Exclusion Criteria:

          -  Patients who present with any current DSM-5 disorder other than MDD which is the focus
             of treatment.

          -  Patients who are homicidal in the opinion of the Investigator or are at suicidal risk
             (any suicide attempts within 12 months prior to Visit 1 [screening] or any suicidal
             intent, including a plan, within 3 months prior to Visit 1 [screening]; C-SSRS answer
             of &quot;YES&quot; on item 4 or 5 [suicidal ideation]; Investigator- or computer-administered
             MADRS score of ≥ 5 on item 10 [suicidal thoughts]; by Investigator clinical
             evaluation).

          -  Patients cannot have any history of substance or alcohol use disorder within 12 months
             prior to Visit 1 (screening) per DSM-5 criteria

          -  Patients must not have a clinically significant comorbid disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Mahableshwarkar, MD</last_name>
    <role>Study Director</role>
    <affiliation>BlackThorn Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerensa Saljooqi</last_name>
    <phone>415-548-5339</phone>
    <email>kerensa@blackthornrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>United States</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson So</last_name>
      <phone>562-246-3800</phone>
      <email>Nelson.So@synexus-us.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>United States</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Lawlor</last_name>
      <phone>714-799-7799</phone>
      <email>andrewlawlor@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>United States, Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Walton</last_name>
      <email>nwalton@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>United States</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rishi Kakar, M.D.</last_name>
      <phone>954-990-6326</phone>
      <email>rkakar@segalinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>United States, Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leticia Griffin</last_name>
      <email>lgriffin@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>United States</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Greenbaum, M.D.</last_name>
      <phone>847-549-7214</phone>
      <email>mgreenbaum@capstoneclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>United States</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Atkinson, M.D.</last_name>
      <email>flcr@flclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>United States</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Grandberry</last_name>
      <phone>901-843-1045</phone>
      <email>cgrandberry@cnshealthcare.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Anhedonia</keyword>
  <keyword>antidepressant</keyword>
  <keyword>Nociceptin</keyword>
  <keyword>NOPR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

